Skip to main content
European Commission logo print header

Nano-assisted digitalizing of cancer phenotyping for immunotherapy

Description du projet

Décision éclairée concernant l’immunothérapie

L’immunothérapie représente une stratégie très prometteuse qui active le système immunitaire d’une personne pour lutter contre le cancer et crée une immunité anticancéreuse. La pratique clinique a toutefois montré que l’immunothérapie est susceptible de provoquer des réactions auto-immunes, ce qui indique qu’il est nécessaire d’en assurer la planification minutieuse. Financé par le Conseil européen de la recherche, le projet ImmunoChip cherche à mettre au point une plateforme capable de prédire l’adéquation d’une immunothérapie pour le patient concerné. Le dispositif ImmunoChip combinera la microfluidique et un réseau nanosensoriel pour étudier les différents aspects d’un cancer spécifique et de son microenvironnement. En plus de fournir des informations sur les composants du système immunitaire, la plateforme aidera les cliniciens à prendre une décision éclairée quant au type de traitement par immunothérapie à prescrire aux patients.

Objectif

Every day cancer takes about 30000 lives worldwide, despite multiple treatments developed in the last 50 years. True revolution in the therapy is demonstrated by the immunooncology relying on multiple routes to activate the immune system, using e.g. Chimeric Antigen Receptors, checkpoints inhibitors. Although demonstrating success in the treatment of e.g. lymphoma, the percentage of patients responding to the immunotherapy is less than 30%. Even more, the activation of immune system does not happen at no cost, leading to severe auto-immune reactions, sometimes with lethal consequences. Therefore, the main question of clinicians is: how to efficiently predict the response/no-response of the patient to the immunotherapy? At present, there is no predictive technological platform combining both, highly sensitive analysis of the cancer immunity and the planning of the strategy for potential therapy.
I consider cancer as a smart self-adapting machine that plays its own set of rules: it generates and quenches the biochemical signals; initiates the iterative loops and builds up feedback controls to create an immune suppressive environment. My idea is to digitalize these mechanisms. ‘ImmunoChip’ will develop a device combining microfluidics with the specific nanosensory network to study elements of the cancer-immunity cycle to bring a new dimension in the field of preclinical immunotherapeutic cancer phenotyping. The information about the immunosuppressive activity of the cancer microenvironment, immune checkpoints, T cells, efficiency of the immunotherapy, will be collected into respective data patterns. The developed ‘ImmunoChip’ platform will help to answer the questions: can the patient be treated with the immunotherapy? How does the tumor protect itself? Which immunotherapy to use? I am sure that improved decision-making in immunotherapy will lead to a transformative treatment results for more patients and will help to save more lives.

æ

Coordinateur

HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV
Contribution nette de l'UE
€ 1 993 875,00
Adresse
Bautzner landstrasse 400
01328 Dresden
Allemagne

Voir sur la carte

Région
Sachsen Dresden Dresden, Kreisfreie Stadt
Type d’activité
Research Organisations
Liens
Autres sources de financement
€ 0,00